MCM
DRUG

MAI Capital Management’s Bright Minds Biosciences DRUG Stock Holding History

MAI Capital Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$73 – 2770
2026
Q1 		$73 Buy
+1
New +$80 ﹤0.01% 4810

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

MAI Capital Management's DRUG Position: Q2 2026 in Review

MAI Capital Management sold out of Bright Minds Biosciences (DRUG) in Q2 2026, closing a stake of 1 share — an estimated $73 sold.

MAI Capital Management first reported a position in DRUG in Q1 2026 and held it in 1 quarter. The position peaked at $73 in Q1 2026. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • MAI Capital Management reported no remaining Bright Minds Biosciences position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 1 Bright Minds Biosciences share in Q2 2026, an estimated $73.
  • MAI Capital Management first reported a position in Bright Minds Biosciences in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's Bright Minds Biosciences position peaked at $73 in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.